written on 10.06.2014
Tags:
,

The Significant Unmet Need in Chronic Lymphocytic Leukemia (CLL)

TAGS: ,

A paradigm shift in the treatment of chronic lymphocytic leukemia (CLL) has taken place over the past decade, as therapies have progressed from providing palliative relief to inducing complete remission, eradicating minimal disease, and improving survival. The development of rituxan (rituximab) and its use in immunochemotherapy regimens has transformed the treatment of CLL and is […]

Latest Report